Amneal Pharmaceuticals named 'Company of the Year'

BRIDGEWATER, N.J. — Amneal Pharmaceuticals on Tuesday announced that the company has won the global “Company of the Year" Award from Generics bulletin, a newsletter which provides commercial and regulatory information for the global generics and biosimilars industries. Presented on Oct. 7 at the Global Generics & Biosimilars Awards 2014 held in Paris, France, the award recognizes Amneal’s rapid growth in North America.  

 

Amneal is the 7th largest U.S. generics manufacturer based on prescriptions dispensed, according to IMS Health. The company’s 76 Food and Drug Administration-approved generic medications and pipeline of 264 products filed with the FDA or in development cover a broad range of therapeutic categories. In addition to high-volume commodity medicines, Amneal’s portfolio contains many high-barrier-to-entry and difficult-to-formulate products and spans almost the entire range of dosage forms in the market.  

 

The company will spend more than $400 million on R&D and capital improvements to its nine manufacturing plants in the U.S. and India over the next two years. Amneal has also invested considerable resources in human capital as well as product development and now employs over 2,600 worldwide.  

 

In addition to its U.S. operations, Amneal is expanding internationally by establishing front-end marketing and distribution capabilities in the U.K., Spain, Germany, the Nordic countries, Switzerland and Australia. The company is also pursuing acquisitions and evaluating strategic partners in Japan, Southeast Asia and Latin America.  

 

“We are deeply honored to be recognized as global ‘Company of the Year’,” said Amneal Co-CEO and Co-Chairman Chirag Patel. “This award lets us know we’re doing all the right things to run a successful, growing enterprise while remaining true to our values - dedication to quality across all operations, maintaining our high standards and ethics and total commitment to our customers, partners and employees.”